Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Breast Cancer
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Breast Cancer
    Massage Reduces Fluid Volume in Lymphoedema Patients but Does Not Improve Arm Function: Presented at ASTRO - (DGDispatch)
    Patients With Centrally Located and Progesterone-Negative Tumours May Need More Aggressive Treatment Following Breast-Conserving Surgery: Presented at ASTRO - (DGDispatch)
    TopAbstracts in Breast Cancer 11/03/2009 - (DGNews)
    Early-Stage, HER2-Positive Breast Cancer Patients at Increased Risk of Recurrence - (DGNews)
    TopAbstracts in Breast Cancer 10/27/2009 - (DGNews)

    News archive

     Recent webcasts/CME - Breast Cancer
    Cutaneous Metastasis of Breast Carcinoma Presenting as Alopecia Neoplastica

    Webcasts/CME archive

     Recent cases - Breast Cancer
      Breast Pseudotumoral Radionecrosis as a Late Radiation-Induced Injury: A Case Report
      Large Family with Both Parents Affected by Distinct BRCA1 Mutations: Implications for Genetic Testing
      Bilateral Swollen Eyelids Occurring During Adjuvant Treatment with Tamoxifen for Early Breast Cancer
      Ruptured Gallbladder as the First Presentation of Breast Cancer
      Synchronous Infiltrating Ductal Carcinoma and Primary Extramedullary Plasmacytoma of the Breast

      Cases archive
        




      my personal edition > breast cancer > news
      divider

        E-Mail this DGDispatch to a colleague

      DGDispatch


      Neoadjuvant Aromatase Inhibitors May Be as Effective as Chemotherapy in Locally Advanced Breast Cancer: Presented at EBCC

      By Paula Moyer

      NICE, FRANCE -- March 27, 2006 -- Preoperative treatment with an aromatase inhibitor may be as effective as neoadjuvant chemotherapy for treatment of patients with locally advanced breast cancer, according research presented here at the 5th European Breast Cancer Conference (EBCC).

      "These results show that preoperative endocrine therapy with aromatase inhibitors offers the same overall objective response and surgery as does chemotherapy in postmenopausal women with locally advanced cancer," said principal investigator Vladimir Semiglazov, MD, head, division of breast cancer, Petrov Research Institute of Oncology, St. Petersburg, Russia.

      In his presentation on March 23rd, Dr. Semiglazov noted that this study is 1 of the first direct comparisons of neoadjuvant endocrine therapy and chemotherapy in the treatment of breast cancer.

      The study involved 239 postmenopausal women with oestrogen receptor-positive breast cancer that was either progesterone receptor-positive or -negative, and was at stage T2 with involvement of 1 to 2 lymph nodes, stage T3 with no more than 1 node involved, or T4 with no nodal involvement.

      Patients were randomised to preoperative treatment with either an aromatase inhibitor -- consisting of either anastrazole (Arimidex) or exemestane (Aromasin) -- or chemotherapy.

      The 121 patients treated with aromatase inhibitors were further randomised to receive either 1 mg daily of anastrozole (61 patients), or 25 mg of exemestane daily (60 patients). Patients were treated for 3 months.

      In the chemotherapy group, 118 patients received 60 mg/m2 of doxorubicin and 200 mg/m2 of paclitaxel every 3 weeks for 4 cycles.

      Study end points were overall objective response -- determined by palpation, mammography, and ultrasound. The researchers also gathered information on how many patients qualified for breast-conserving surgery and radiotherapy, and how many required mastectomy.

      In the overall group, 62.2% of the endocrine therapy group and 63.5% of the chemotherapy group responded to treatment. Median time to clinical response was 57 days in the endocrine group and 51 days in the chemotherapy group.

      Pathologic complete response was achieved in 3.2% of patients in the endocrine group and 5.9% of those on chemotherapy. Of patients on endocrine therapy, 9.0% and 8.5%, respectively, had disease progression. None of these differences were statistically significant, Dr. Semiglazov said.

      He concluded that the study's findings show an encouraging potential for the use of aromatase inhibitors in the neoadjuvant setting for certain patients with locally advanced disease.


      [Presentation title: Primary Endocrine Therapy Vs Chemotherapy in Postmenopausal ER-Positive Breast Cancer Patients. Abstract 238]



      E-Mail this DGDispatch to a colleague   To print, use this version






      All contents Copyright (c) 1995-2009 Doctor's Guide Publishing Limited. All rights reserved.



      The NTK initiative. Physicians helping physicians identify Need-To-Know science
         Feedback
      Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
      Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
      1
      2
      3
      4
      5
      6
      7
      Send